Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript

SA Transcripts 161.99K Followers Follow Bausch + Lomb Corporation ( BLCO ) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate August 24, 2026 5:30 PM EDT Company Participants Brenton L. Saunders - CEO & Director Yehia Hashad - Executive VP of Research & Development and Chief Medical officer Mayssa Attar - Senior VP of Pharmaceutical & Head of Consumer R&D Conference Call Participants Patrick Andrew Wood - UBS Investment Bank, Research Division Gursimran Kaur - Wells Fargo Securities, LLC, Research Division Joanne Wuensch - Citigroup Inc., Research Division Aidan Leahy Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good evening, and welcome to Bausch + Lomb's R&D Update Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Brent Saunders, Chief Executive Officer. Please go ahead. Brenton L. Saunders CEO & Director Great. Thank you, Operator. Thank you, everyone, for joining us on such short notice. We really appreciate you getting on the call today. I'm joined with my colleagues, Yehia Hashad, our Head of R&D; and Mayssa Attar, Head of Pharmaceutical R&D. And we're looking forward to taking you through the presentation and, more importantly, taking any questions you have. So Allison, if we could jump to the next slide. Perfect. So today, we're sharing results on 2 first-in-class programs that further reinforces why we believe in our pipeline. First, on our dual-action dry eye medicine, this is the first therapy designed to address both inflammatory and evaporative drivers of dry eye in a single treatment, and we will be moving it into Phase III. As you'll learn later throughout this conference call, Phase II showed a strong statistical significant effect at Day 15, much faster than we